OBJECTIVE To provide domestic innovative pharmaceutical enterprises practical advice on patent strategy and innovation capacity-building. METHODS Choose the first class innovative drug NBP as study subject, make an empirical study from three aspects, including patent creation, management and implementation, about how to take full advantage of the national innovation policies and patent strategy to improve the innovation capability of enterprises to ensure its sustainable development.RESULTS The patent strategy of NBP turns out to be a very big success. CONCLUSION CSPC has developed a virtuous cycle, in which patent strategy and innovation capacity-buildingfacilitate each other, its successful experience is worth learning for high-tech enterprises.
DING Jin-xi, MENG Li-li, ZHANG Jin-feng.
Pharmaceutical Corporate Patent Strategy and Innovation Capacity-Building under the Framework of the Strategic Emerging Industries[J]. Chinese Pharmaceutical Journal, 2014, 49(5): 431-436 https://doi.org/10.11669/cpj.2014.05.021
FENG X Q. Enterprise Intellectual Property Strategy(企业知识产权战略) . 2nd ed. Beijing: Intellectual Property Publishing House, 2005:10-11. GUO D H. Research on patent strategic of multinational pharmaceutical companies in china and its enlightenment to traditional chines medicine industry. China Academy of Chinese Medical Science, 2008. SHAO R. Theory and Practice of Chinese Pharmaceutical Law(中国药事法理和实务). Beijing: China Medical Science Press, 2010:261-262. BEIJING BUSINESS DAILY: CSPC entered into Korean market. .Sina Finance, 2007 . http://finance.sina.com.cn/roll/20071122/00131806992.shtml. ZHONG Z H. What makes an innovative drug wait for 2 years before entering the medical insurance catalog. China Prescr Drug(中国处方药), 2009, 7(88):13.